Abstract: The present invention relates to a method of preparing a separation matrix comprising at least one insoluble carrier to which sulphate ligands have been attached via extenders, which method comprises coupling, in a first step, of the sulphate ligands to the extenders and, in a subsequent step, attaching the extenders to an insoluble carrier. The invention also relates to a separation matrix comprised of at least one insoluble carrier to which sulphate ligands have been attached via extenders. Advantageously, no sulphate ligands are directly attached to the insoluble carrier. The extenders may be natural polymers, such as dextran, and the insoluble carrier may be made from natural polymers, such as agarose, or synthetic polymers. The invention also relates to a method of purifying virus, such as influenza virus, using a separation matrix according to the invention.
Type:
Grant
Filed:
September 26, 2007
Date of Patent:
July 9, 2013
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Inger Andersson, Andreas Axen, Peder Bergvall, John Clachan, Camilla Estmer-Nilsson, Lena M. Sandberg
Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
Type:
Grant
Filed:
May 6, 2010
Date of Patent:
June 25, 2013
Assignee:
Crucell Holland B.V.
Inventors:
Mark Throsby, Robert Heinz Edward Friesen, Theodorus Hendrikus Jacobus Kwaks, Mandy Antonia Catharina Jongeneelen
Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.
Abstract: Provided is a fusion protein, which comprises human papillomavirus E7 antigen, virus capsid protein and molecular chaperone. Also provided is a macromolecule with immunogenicity aggregated by the fusion proteins. The particle morphology of the macromolecule is different from that of the virus-like particle. The macromolecule can be used for treatment of human papillomavirus relating diseases.
Type:
Grant
Filed:
June 18, 2008
Date of Patent:
June 25, 2013
Assignees:
Shanghai Zerun-Ankegens Biopharmaceutical Company, Ltd., Yunxu CAO
Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
Abstract: The invention provides a method for enhancing expression of a transgene in a host cell, which includes the steps of inserting a capsid promoter element (Pcap), or a sequence comprising the reverse complement of the capsid promoter element (PcapR), into a mammalian expression cassette upstream (5?) of a cytomegalovirus immediate/early enhancer/promoter region (Pcmv); inserting the transgene into the expression cassette downstream (3?) of the cytomegalovirus immediate/early enhancer/promoter region; inserting a vector containing the expression cassette into the host organism; and causing expression of the transgene. The capsid promoter element (Pcap) is typically from a circovirus, parvovirus or anellovirus. The transgene is typically expressed at a higher level than when expressed by a vector containing the expression cassette without the transcriptional control element. An expression cassette, vector, DNA vaccine, pharmaceutical composition and method of treatment are also claimed.
Type:
Grant
Filed:
November 8, 2006
Date of Patent:
June 11, 2013
Assignees:
South African Medical Research Council, University of Cape Town
Inventors:
Edward Peter Rybicki, Fiona Lesley Tanzer
Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
Abstract: The present inventors developed three 4a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 4a reference strain ED43. The 4a/2a junction in NS2 was placed after the first transmembrane domain (?), in the cytoplasmic part (?) or at the NS2/NS3 cleavage site (y). Following transfection of Huh7.5 cells with RNA transcripts, infectious viruses were produced in the ED43/JFH1-? and -y cultures only. Compared to the 2a control virus, production of infectious viruses was significantly delayed. However, in subsequent passages efficient spread of infection and high HCV RNA titers were obtained. Infectivity titers were approximately 10-fold lower than for the 2a control virus. Sequence analysis of recovered 4a/2a recombinants from 3 serial passages and subsequent reverse genetic studies revealed a vital dependence on a mutation in the NS2 4a part. ED43/JFH1-? further depended on a second NS2 mutation.
Abstract: The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases.
Type:
Grant
Filed:
September 30, 2009
Date of Patent:
May 28, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offenlichen Rechts
Inventors:
Laurent Daeffler, Jurg Nuesch, Jean Rommelaere
Abstract: Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus K5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.
Type:
Grant
Filed:
August 26, 2008
Date of Patent:
May 21, 2013
Assignee:
Temasek Life Sciences Laboratory Limited
Abstract: The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins.
Type:
Grant
Filed:
October 26, 2011
Date of Patent:
May 14, 2013
Assignee:
The United States of America as Represented by the Secretary of the Navy
Inventors:
Monika Simmons, Kevin R. Porter, Wellington Sun
Abstract: A recombinant DNA construct, recombinant vectors and host cells comprising the dimers of DNA A and DNA B of Mungbean Yellow Mosaic India Virus (MYMIV) in a single Ti plasmid are provided herein.
Type:
Grant
Filed:
December 8, 2008
Date of Patent:
May 7, 2013
Assignee:
National Institute for Plant Genome Research
Abstract: The present invention provides a method of pretreating a specimen, which allows measurement according to an immunoassay to be carried out on a specimen from nasal secretion while preventing non-specific reactions. According to this method, the specimen from nasal secretion is treated with a protease beforehand and then an immunoassay is performed. As the protease, it is preferable to use semi-alkaline protease (EC 3.4.21.63). Furthermore, it is preferable that a substance to be pretreated by the pretreatment method according to the present invention is an influenza virus contained in the specimen from nasal secretion. The immunoassay preferably is an immunoagglutination assay. Examples of the immunoagglutination assay include a turbidimetric immunoassay, a latex turbidimetric immunoassay, and a latex agglutination assay that is performed on a slide glass.
Abstract: Methods of making and compositions that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a membrane fusion domain, a transmembrane domain and a cytoplasmic domain. Compositions can further include a Toll-like Receptor agonist and a carrier protein.
Type:
Grant
Filed:
March 6, 2007
Date of Patent:
April 16, 2013
Assignee:
VaxInnate Corporation
Inventors:
Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
Abstract: The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Methods of using said cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of said virus for the purpose of vaccine production or diagnosis, are also provide by the present invention.
Type:
Grant
Filed:
July 23, 2008
Date of Patent:
April 16, 2013
Assignee:
Universiteit Gent
Inventors:
Peter Delputte, Hans Nauwynck, Hanne Van Gorp
Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
Type:
Grant
Filed:
October 24, 2011
Date of Patent:
April 9, 2013
Assignee:
Transgene S.A.
Inventors:
Daniel Malarme, Yves Cordier, Claude Sene
Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
Type:
Grant
Filed:
October 24, 2011
Date of Patent:
April 9, 2013
Assignee:
Transgene S.A.
Inventors:
Daniel Malarme, Yves Cordier, Claude Sene
Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.